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Abstract
Background: Plant viruses such as Cowpea mosaic virus (CPMV) are increasingly being developed for applications in
nanobiotechnology including vaccine development because of their potential for producing large quantities of antigenic
material in plant hosts. In order to improve efficacy of viral nanoparticles in these types of roles, an investigation of the
individual cell types that interact with the particles is critical. In particular, it is important to understand the interactions of a
potential vaccine with antigen presenting cells (APCs) of the immune system. CPMV was previously shown to interact with
vimentin displayed on cell surfaces to mediate cell entry, but the expression of surface vimentin on APCs has not been
characterized.
Methodology: The binding and internalization of CPMV by several populations of APCs was investigated both in vitro and in
vivo by flow cytometry and fluorescence confocal microscopy. The association of the particles with mouse gastrointestinal
epithelium and Peyer’s patches was also examined by confocal microscopy. The expression of surface vimentin on APCs was
also measured.
Conclusions: We found that CPMV is bound and internalized by subsets of several populations of APCs both in vitro and in
vivo following intravenous, intraperitoneal, and oral administration, and also by cells isolated from the Peyer’s patch
following gastrointestinal delivery. Surface vimentin was also expressed on APC populations that could internalize CPMV.
These experiments demonstrate that APCs capture CPMV particles in vivo, and that further tuning the interaction with
surface vimentin may facilitate increased uptake by APCs and priming of antibody responses. These studies also indicate
that CPMV particles likely access the systemic circulation following oral delivery via the Peyer’s patch.
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Introduction
Viruses are increasingly being used in nanotechnology applica-
tions for a variety of purposes as diverse as material science, vaccine
development, and therapeutic design. For many years animal
viruses have been developed for gene delivery and gene therapy
purposes [1]. More recently, other pathogens such as plant viruses,
bacteriophages and viruses of Archaea are increasingly being used
for nanobiotechnology purposes because of their relative structural
and chemical stability, ease of production, and lack of toxicity and
pathogenicity in animals or humans [2,3,4,5]. In particular, plant
viruses have been at the forefront of efforts to develop novel
vaccines, in part because of the potential for producing large
quantities of antigenic material in plant hosts, as well as the
possibility for developing orally-bioavailable antigens. A variety of
plant pathogens such as cowpea mosaic virus (CPMV) [2,3,4,5,6,7],
cucumber mosaic virus (CMV) [8,9], alfalfa mosaic virus (AlMV)
[10], tobacco mosaic virus (TMV) [11,12,13] and papaya mosaic
virus (PapMV) [14] have been exploited for vaccine purposes,
whereby the viruses are modified to present antigens through
genetic introduction of foreign epitopes and proteins, thus
combining engineering of the multivalent antigen with large-scale
production of the antigen in plants.
CPMV-based vaccines in particular have been shown to induce
neutralizing antibodies against multivalently-displayed epitopes
derived from infectious agents [15,16,17,18]. Advantages of using
CPMV particles as a vaccine delivery system include the natural
resistance of CPMV to high temperature, low pH and proteolysis
as well as the potential for large-scale production in the natural
host black-eyed pea or Vigna unguiculata ($1.0 g of virus per
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capsid, is a member of the picornavirus superfamily of viruses.
CPMV capsids are composed of 60 copies of the large (L) and
small (S) protein subunits assembled around an RNA genome
[16,18,19]. Antigenic epitopes are commonly displayed by
introduction of peptide sequences in regions of the genome
encoding the capsid surface loops. In addition, the surface may be
chemically modified for direct attachment of peptides and other
ligands [20,21,22,23]. A variety of bioconjugation methods have
been developed, with surface lysines or introduced cysteines most
typically utilized.
CPMV chimeric viruses displaying foreign epitopes from
pathogens including HIV-1 [6,7], mink enteritis virus [17],
Staphylococcus aureus [4,5] and Pseudomonas aeruginosa [3,5] induce
strong humoral immune responses against those pathogens in vivo,
some of which induce protective levels of immunity. It is thought
that the multivalent nature of antigen display on the virus particle
surface facilitates efficient induction of epitope-specific responses.
Nevertheless, relatively little is known about how CPMV or other
plant viruses interact with antigen presenting cells (APCs) either in
vitro or following delivery in vivo.
Previously, we studied the bioavailability of CPMV in vivo after
oral or intravenous delivery in mice. CPMV has been extensively
studied in vivo [24,25]. We demonstrated that following delivery in
mice, CPMV was found in virtually all tissues for several days after
administration [26]. In addition, we showed that CPMV was
stable under gastric conditions, and following oral delivery we also
observed virus throughout the mice suggesting that the virus had
crossed the gastrointestinal epithelium, perhaps by interaction with
Peyer’s patches (PP). These secondary lymphoid organs are
located in the terminal ileum of the small intestine and contain
dendritic and other cells of the immune system. CPMV was also
detected in spleen and lymph nodes, however the individual cell
types that interacted with virus were not determined [26].
The potential for the use of CPMV and other plant virus
particles for in vivo vaccine and other applications require a better
understanding of interactions with APCs in vitro and in vivo. The
most efficient, or ‘‘professional’’ APCs include dendritic cells
(DCs), macrophages and B cells. These cell types are optimally
equipped to present antigens to T-cells primarily because of their
capabilities in antigen capturing. DCs are the most potent APCs
because they are highly specialized in internalizing and processing
antigens. Immature DCs (imDCs) ingest antigens via a number of
mechanisms, including receptor-independent macropinocytosis,
receptor-dependent phagocytosis, and receptor-mediated endocy-
tosis via clathrin-coated pits or caveolae [27,28,29,30,31,32].
Mature DCs (mDC) express high levels of co-stimulatory
molecules CD40, CD80 and CD86, which synergize with antigen
in the activation of naı ¨ve T-cells. In the mouse there are three
known DC subsets in the spleen and three in the intestinal PP, and
these are discernable based on surface marker expression. CD8a
+
and CD8a
2 DC subsets are often considered to be of lymphoid
and myeloid origin respectively, although the developmental
origin of these cells remains controversial [33,34,35]. The mouse
spleen contains myeloid (CD11c
+, CD11b
+, CD8
2) lymphoid
(CD11c
+, CD11b
2, CD8a
+) and plasmacytoid DC (CD11c
+,
B220
+), the latter subtype expressing the CD45 isoform (B220) that
is normally expressed by B cells [36,37,38]. In the intestinal PP, a
third subset of CD11c
+ DCs distinct from lymphoid and myeloid
phenotypes, has been characterized which does not express either
high levels of CD11b or CD8a molecules and are thus defined as
double negative DCs (CD11b
2, CD8a
2) [39,40]. Macrophages,
natural killer (NK) cells, and B-cells also can act as APCs, albeit
with less potency than DCs [41,42].
The ability of CPMV to bind and be internalized by several
populations of APCs was characterized in vitro. The uptake of
CPMV particles by APCs in vivo following intravenous, intraper-
itoneal or oral dosing was investigated by flow cytometry and
fluorescence confocal microscopy. Next, the association of CPMV
particles with gastrointestinal epithelium and PPs was examined by
ileal loop ligation and confocal microscopy. Finally the expression
of CPMV binding proteins on APCs was evaluated by flow
cytometry.
Results
APCs Bind and Internalize CPMV Particles In Vitro
Several fluorescently-labeled versions of CPMV were made to
visualize CPMV by fluorescence microscopy and detect it by
FACS. Fig. S1A shows a space-filling model of CPMV with the
300 naturally-occurring exposed lysine residues labeled in red,
although typical labeling using NHS-ester forms of fluorescent
dyes yields a maximum of 240 dyes/particle [20]. For most of the
experiments Alexa Fluor 488 (AF488) was conjugated to the
particles, which has a stronger and more stable signal at varying
pH. The lysine residues were conjugated with NHS-AF488,
obtaining an average of 71.33 dyes per particle to generate
CPMV-AF488. For some studies a cysteine mutant labeled with
maleimide-fluorescein was used as well. Fig. S1B shows a
genetically modified CPMV (vEFa) containing a cysteine residue
in each of the large subunits of the capsid [20], and the 60
addressable cysteine residues are indicated in blue. CPMV-vEFa
particles bioconjugated with maleimide-F were labeled at 23 dyes
per virus particle to yield CPMV-F. The use of either CPMV-
AF488 or CPMV-F in the experiments is noted.
To analyze the ability of APCs to capture and internalize
CPMV particles, we used the fibroblast cell lines BalbCl7 and
MC57, as well as immature dendritic cells (imDCs) derived from
mouse bone marrow, and primary mouse splenocytes. Although
the BalbCl7 and MC57 cell lines are not considered professional
APCs, they have been used extensively for antigen presentation in
cytotoxic T-cell recognition and killing assays [43,44,45].
CPMV-AF488 was used to study the binding and internaliza-
tion of CPMV in fibroblast BalbCl7 and MC57 cell lines, and
immature murine bone-marrow derived DCs (imDCs). Cells were
fixed and incubated with virus particles overnight at 4uC and
visualized by fluorescence microscopy. As shown in Fig. 1 (A–F)
these three cell types appeared fluorescent on their surface,
suggesting that the CPMV particles were able to bind to their
membranes. After an overnight incubation the majority of
BalbCl7 and MC57 cells were CPMV-positive, but only 40% of
the imDC population bound CPMV (Fig. 1A–C). To evaluate the
ability of APCs to internalize CPMV particles in vitro by
fluorescence confocal microscopy, CPMV-F was used to detect
the uptake of the particles by BalbCl7 and MC57 cell lines. The
cells were cultured overnight with CPMV-F, fixed and stained
with DAPI to visualize the nucleus. As shown in Figure 1 (G–H
and J–K) both cell lines contained green fluorescent vesicle-shaped
structures in the cytoplasm. Bone marrow derived imDCs were
also analyzed with the same procedure but using CPMV-AF488.
As shown in Figure 1 (I and L) imDCs also internalized CPMV.
These results support our previous finding of CPMV particle
localization within LAMP-2 and ß-COP-bearing Golgi and
lysosome organelles both in BalbCl7 cells [24] and murine DCs
[25].
Analysis by flow cytometry and confocal microscopy do not
allow confirmation that the fluorescence within the cell is from
intact CPMV particles. Endothelial cells and macrophages
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PLoS ONE | www.plosone.org 2 November 2009 | Volume 4 | Issue 11 | e7981Figure 1. Binding and internalization of CPMV nanoparticles in vitro. (A–F) Binding of CPMV to (A) BalbCl7 cells, (B) MC57 Cells, and (C) bone
marrow-derived immature DCs (imDC). Cells were fixed with 2% formaldehyde and incubated with CPMV-AF488 (green) on ice overnight. The cells
were washed and stained with Hoechst 33258 to visualize the nucleus (blue). (G and H) Uptake of CPMV-F by the cell lines BalbCl7 and MC57,
respectively. (I) Uptake of CPMV-AF488 by imDCs. Cells were incubated overnight with the fluorescent virus particles (in green), washed with PBS,
fixed, and stained with DAPI (G and H) or Hoechst 33258 (I) to visualize the nucleus (blue). (D–F and J–L) Transmission light image showing the body
of the cells. The cells were visualized by fluorescence microscopy using the 20X objective. (M–O) Surface vimentin expression in Caco-2 cells stained
with DAPI (blue, M–O), wheat germ agglutinin- AF555 (red, M, O), and specific antibodies to vimentin conjugated to AF647 (green, N–O). Cells were
fixed and incubated with WGA one hour RT, anti-vimentin V9 antibody, 1.5 hour RT, and secondary AF647 one hour RT (M–O). Cells were visualized
by fluorescence microscopy using the 60X objective (M–O).
doi:10.1371/journal.pone.0007981.g001
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been shown by transmission electron microscopy to take up intact
CPMV particles [25]. It is possible that, particularly in cell types
like NK cells which are not known to have significant phagocytic
properties, the fluorescence observed represents virus particle
cleavage products or subunits. In any case, it is currently unknown
what mechanism antigen-presenting and other cells utilize to
internalize CPMV, so the importance of phagocytic ability in this
process is not known.
Quantitation of CPMV Binding and Internalization by DCs
In Vitro
Since DCs are the most potent APCs, their capacity to bind and
internalize CPMV particles in relation to their maturation state
was analyzed further. ImDCs were generated from bone marrow
progenitors using granulocyte macrophage colony-stimulating
factor (GM-CSF) [46]. After 9 or 10 days of culture 87.7% of
the cell population differentiated into CD11c
+/CD11b
+ double
positive DCs. These cells expressed low amounts of the co-
stimulatory molecules CD80 (88.5%) and CD86 (84.1%), and
were negative for CD40.
To characterize CPMV binding the cells were incubated with
CPMV-AF488 for 3 hours on ice, washed, stained and analyzed
by FACS. The results showed that 40% of the imDCs bound the
particles, with two populations of cells observed: a small
population with high binding (4%; approximately 100-fold higher
than background) and a second one with low binding (36%;
approximately 10-fold higher than background), (Fig. 2A). Further
characterization showed that the majority of cells that bound
CPMV expressed higher levels of CD11c (74.0%) and CD11b
(84.1%) molecules, while having low expression of CD80 (89.4%)
and CD86 (89.7%) (Table 1). The imDC population that did not
bind CPMV was 53.7% CD11c
high, 53.0% CD11b
high, 89.1%
CD80
low and 78.3% CD86
low. These results indicated that the
bone marrow derived imDCs that are more likely to bind CPMV
have a higher expression of the CD11c and CD11b proteins, but
CD11c
high and CD11b
high cells that do not bind the virus are also
present in the culture. These results suggest that not all of the
imDCs derived from bone marrow have the ability to bind CPMV
possibly because not all of them express the receptor protein
vimentin that binds the CPMV particles. Similar results were
observed when internalization of the particles was studied
(Table 1).
To establish whether the binding of CPMV to DCs is specific,
we performed a competition assay using lys-AF488 labeled and
unlabeled CPMV particles. DCs were labeled with the cell
markers CD11c and CD11b, and 5610
5 or 1610
6 stained cells
were incubated on ice with different concentrations of unlabeled
CPMV particles (from 0 to 100 mg of particles, where 1 mgo f
CPMV contains 1610
11 particles). After washing, the cells were
incubated with 1 mg of CPMV-AF488 for three hours on ice. The
ratios of labeled to unlabeled CPMV particles were 1:0, 1:1, 1:10,
1:100 and 1:1000. Due to the presence of two groups of DCs with
high and low binding respectively (Fig. 2A), we analyzed these two
populations separately. After acquisition, the CD11c/CD11b
double positive cells were selected for binding analysis. The results
showed a decrease in the binding capacity of the cells to labeled
particles as the amount of competing unlabeled particles increased
(Fig. 2B and 2C). As expected, DCs showed a greater degree of
competition at lower concentrations of unlabeled CPMV particles
than did the CPMV high binding DCs. These results confirm that
the binding of CPMV to the cells is specific and there is an
approximately 1–2 order of magnitude difference in CPMV
binding between the two DC populations.
Vimentin Expression on APCs
In our studies of CPMV trafficking in mouse, we identified a
54 kD cell-surface CPMV binding protein that was expressed on
cells with APC activity (MC57) as well as vascular endothelial cells.
We have subsequently identified this protein as a surface-expressed
form of the cytoskeletal protein vimentin. The binding of CPMV
to vimentin was shown to be dose-dependent [47,48]. Vimentin
forms intermediate filaments in the cytoplasm of cells of
mesenchymal origin, but a surface-expressed form has recently
been demonstrated on cell types including macrophages and T-
cells [49,50]. Presently, it is unknown to what extent APCs in the
mouse are able to bind and internalize CPMV and whether this
correlates with surface vimentin expression.
Variation in level of binding and internalization of CPMV by
different cell types could be explained by variation in the level of
surface expressed vimentin. Membrane stain wheat-germ agglu-
tinin (WGA, red) is compared with vimentin staining (green) to
verify surface vimentin versus internal vimentin in Caco-2 cells
(Fig. 1, M–O).
The distribution of CPMV binding in Fig. 2A, which includes
high, low, and no binding populations, could also partially be
explained by the partite distribution of surface vimentin expression
on cells of the immune system. FACS analysis of MC57 cells
reveals that some cells express surface vimentin at high levels,
while some express at low levels, and some are indistinguishable
from secondary antibody background (Fig. 2E). In fact, about 40%
of MC57 and Caco cells express some level of surface vimentin,
while an even smaller percentage is shown on BalbCl7 and RAW
macrophage cells (Fig. 2F).
Immature Dendritic Cells and Other APCs Display Surface
Vimentin In Vitro
After confirming that imDCs were able to bind and internalize
CPMV, it became important to investigate whether the CPMV
binding protein vimentin was displayed on their surface. ImDCs
(62.8% were CD11c
+/CD11b
+) were generated from bone
marrow by the method described previously. Surface vimentin
was stained and the cells were analyzed by FACS. Results
indicated that 22.1% of double positive DCs displayed surface
vimentin, and the rest were indistinguishable from secondary
antibody controls (Fig. 3). These findings confirm that in vitro,
surface vimentin is present on unactivated DCs, which are able to
bind and internalize CPMV. To better define the correlation
between vimentin surface expression and CPMV uptake in APCs,
BalbCl7 cells were incubated with CPMV for durations of 3 and
24 hours. These cells were then fixed and surface vimentin was
stained with specific antibodies. After three hours, 81% of CPMV-
AF488 positive cells were also positive for surface vimentin,
compared with 51% of the total population of cells (Figure S2).
Cells incubated with CPMV-AF488 for 24 hours did not show as
strong a correlation (62% of CPMV-AF488 positive cells are
positive for vimentin). These results are in good agreement with
our previous studies correlating surface vimentin and CPMV
binding [47,48].
APCs Internalize CPMV Particles In Vivo
To determine whether APCs can internalize CPMV in vivo, C57
BL/6 mice were inoculated intraperitonealy using 100 mgo f
CPMV-AF488 (1610
13 virus particles). After four hours, spleno-
cytes were obtained and visualized by fluorescence microscopy.
Fig. 4A shows a sample of total splenocytes containing green
fluorescence, indicating CPMV uptake. Cell subsets were
identified using the antibody markers: PE-CD11c (DCs), PE-
Nanoparticle-APC Interactions
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visualized under a fluorescence microscope. As shown in Fig. 4
(C–F), DCs (CD11c
+), B220
+ cells, CD8a
+ cells and natural killer
cells (NK 1.1
+) were able to internalize CPMV in vivo.
Based on these findings, the in vivo uptake of CPMV particles by
different populations of APCs was further quantified after
intraperitoneal, intravenous, or oral inoculation. For the first two
routes 100 mg of CPMV-AF488 was used and detection was
performed after 4 hours, while for the oral route the dose of 1 mg
of labeled particles (1610
14 virus particles) per mouse was required
to detect CPMV in APCs at 20 hrs post-dosing. Splenocytes were
obtained, stained and analyzed by FACS to evaluate lymphoid
DCs (CD11c
+ CD8a
+), myeloid DCs (CD11c
+ CD8a
2), plasma-
sytoid DCs (CD11c
+ B220
+), macrophages (CD11c
2, CD11b
+), B
cells (CD11c
2 B220
+), and natural killer cells (NK 1.1
+). As shown
in Fig. 5, all investigated cell populations were able to internalize
CPMV particles following each route of administration, corrob-
orating the results observed by immunofluorescence microscopy
(as an example, the flow cytometry data for intraperitoneal
injection is also shown in Fig. S3). Fig. 5A also shows that the
intraperitoneal route generated 5% more CPMV positive
lymphoid DCs (CD11c
+ CD8a
+) than did the intravenous route,
whereas the intravenous route of inoculation resulted in a higher
percentage of macrophages, B cells and NK cells internalizing
CPMV particles. In comparison with these routes, the amount of
cells which had taken up CPMV particles after oral gavage is
about 10 fold lower for lymphoid DCs (CD11c
+ CD8a
+) and more
than 100 times lower for the rest of the cells (Fig. 5B). Moreover,
Figure 2. Binding and uptake of CPMV particles by imDCs. (A, B and C) CPMV binding. (A) FACS analysis of a culture of ten days differentiated
bone marrow cells. Cells were incubated on ice for 3 hours with CPMV-AF488 (dashed line), washed and stained with APC-CD11c and PE-CD11b
antibody markers to identify imDCs. PBS was added to the control cells (solid line). (B and C) CPMV competition assay. After labeling with APC-CD11c
and PE-CD11b markers 1610
6 cells (B) or 5610
5 cells (C) per well were incubated on ice with different amounts of unlabeled CPMV (0 mg, 1 mg, 10 mg,
100 mg and 1000 mg). After washing, 1 mg of CPMV-AF488 was added to each well generating a ratio of 1:0, 1:1, 1:10, 1:100 and 1:1000 of CPMV-
AF488 to unlabeled CPMV. The black columns represent the high binding imDCs and the white columns represent the low binding imDCs. (D) FACS
analysis of CPMV uptake by imDCs. Cells were incubated for two hours with CPMV-AF488 (dashed line) at 37uC and 5% CO2, washed and stained with
APC-CD11c and PE-CD11b antibodies and analyzed by FACS to quantify the internalization of CPMV particles into CD11c
+/CD11b
+ DCs. PBS was
added to the control cells (solid line). (E and F) FACS analysis of surface vimentin expression on MC57 (E, F), BalbCL7, RAW macrophages, and Caco
cells (F). Cells were incubated one hour, 4uC with anti-vimentin V4630 antibody, then one hour, 4uC with secondary AF647 antibody.
doi:10.1371/journal.pone.0007981.g002
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+ CD8a
+ (lymphoid) DCs take up CPMV relatively more
efficiently after oral gavage. The decrease in detection of CPMV
positive cells after oral gavage is probably due to partial transport
of the particles across the intestinal epithelium or possibly due to
partial cleavage of the fluorescent dye from the particles in the
gastrointestinal tract. Fig. 5C also confirms that surface vimentin is
present on splenocytes including CD8
+, CD11b
+, NK1.1
+, and
B220
+ cell populations.
CPMV Particles Interact with PP in the Intestinal
Epithelium
As we had previously shown that CPMV entered the
bloodstream following oral inoculation and could be found in
splenocytes after oral gavage (Fig. 5), we wished to observe the
interaction between CPMV and the intestinal epithelium and
Peyer’s patch. Ileal loops containing a single PP were injected into
the intestinal lumen with 200 mg of CPMV-AF488 and 20 mg
UEA rhodamine, a lectin that specifically binds to M cells. As
shown in Fig. 6A, CPMV particles were co-localized with the UEA
lectin in the sub-epithelial dome (SED) of the PP, indicating that
CPMV crossed the intestinal barrier through M cells localized on
the follicle-associated epithelium (FAE). To investigate which types
of cells within the PP associated with CPMV particles, the PP cells
were analyzed by flow cytometry. After incubating the ileal loops
with 200 mg of CPMV-AF488 for 1 hour, the cells from two
individual PP were stained and analyzed by FACS to evaluate
lymphoid DCs (CD11c
+ CD11b
2 CD8a
+), myeloid DCs (CD11c
+
CD11b
+ CD8a
2), double negative DCs (CD11c
+ CD11b
2
CD8a
2) and macrophages (CD11c
2, CD11b
+). The results
indicate that the myeloid DC subpopulation primarily takes up
CPMV in the PP. Macrophages did not take up CPMV particles
in the PP (not shown). However, from the total DC population
(CD11c
+ cells) in the PP, the percentage of myeloid and double
negative DCs taken up CPMV particles was similar (not shown).
The results suggest that the route of particle administration
influences the cellular subtypes that are accessible to CPMV. We
also demonstrated that Caco-2 cells, a gastrointestinal epithelial
cell line similar to M cells, display vimentin on the cell surface and
a subpopulation is able to bind and internalize CPMV particles in
vitro (Fig. 1, M–O). Together these results indicate that a variety of
APC populations in the PP and spleen are capable of internalizing
CPMV, and the interaction with CPMV is consistent with display
of the CPMV-binding protein, surface vimentin.
Discussion
This study shows that in vitro, CPMV binds to and is internalized
by APCs such as BalbCl7, MC57 and imDCs derived from mouse
bone marrow. Moreover, DCs, macrophages, B cells and NK cells
have the ability to capture CPMV particles in vivo following
intravenous, intraperitoneal, and oral administration. Interaction
Figure 3. Surface vimentin expression on imDCs. (A) FACS analysis of vimentin on the surface of immature dendritic cells. (B) Surface vimentin
positive and negative CD11b
+ CD11c
+ cell populations.
doi:10.1371/journal.pone.0007981.g003
Table 1. Percentage of dendritic cell subpopulations positive and negative for CPMV.
CD11c
high CD11c
low CD11b
high CD11b
low CD80
high CD80
low CD86
high CD86
low
Binding
CPMV(+) 74.0 26.0 84.1 15.9 10.6 89.4 10.3 89.3
CPMV(2) 53.7 46.3 53.0 47.0 10.8 89.1 21.7 78.3
Internalization
CPMV(+) 88.5 11.5 86.0 13.9 8.4 91.5 5.4 94.5
CPMV(2) 10.6 89.4 1.4 98.5 15.0 85.0 16.3 83.6
FACS analysis of immature dendritic cell subpopulations ability to bind and internalize CPMV-AF488. Subpopulations include high and low expression of CD11c, CD11b,
CD80, and CD86. The majority of cells that bound and internalized CPMV expressed higher levels of CD11c and CD11b molecules, while having low expression of CD80
and CD86.
doi:10.1371/journal.pone.0007981.t001
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CPMV binding protein, surface vimentin. Following oral admin-
istration, CPMV associated with the gastrointestinal epithelium, in
particular PP. CPMV could also be detected in APCs isolated
from PP. Together these results indicate that CPMV can interact
with APCs by a variety of routes of administration.
Studies of CPMV binding and internalization by flow cytometry
showed that APCs interacted with CPMV. In vitro, only about 40%
of the imDCs (CD11c
+ and CD11b
+) were CPMV positive. The
capacity of the imDCs to bind CPMV is not related to the degree
of differentiation or level of expression of the CD11c or CD11b
markers, since 53% of the imDC population that did not bind
CPMV expressed high levels of these molecules. Instead, this
capacity is likely better related to the presence and level of
expression of the CPMV binding protein, vimentin, on the cell
surface. We have shown that in vitro, BalbCl7 cells which have
recently (3 hr incubation) internalized CPMV particles are more
likely to have vimentin on their surface (81%) than those which
have have incubated for 24 hours (62%). However, each of the
CPMV-AF488 positive populations are more likely to display
surface vimentin than the total population of BalbCl7 cells
displaying surface vimentin (51%). ImDCs are specialized to take
up antigens, and we have demonstrated 88.5% of bone marrow-
derived imDCs expressing high levels of CD11c and CD11b
molecules efficiently internalized CPMV particles. As we expected,
CPMV particles were also efficiently internalized by DCs after in
vivo inoculation. Following i.p. or i.v. routes of inoculation, CPMV
particles were present in lymphoid, myeloid, and plasmocytoid DC
populations and after oral gavage the lymphoid cells in the spleen
had the highest percentage of internalization.
Figure 4. In vivo uptake of CPMV particles. (A) Spleen cells were purified 4 hours after i.p. inoculation with 100 mg CPMV-AF488 and stained with
DAPI. (B) Transmission light microscopy image showing the body of the spleen cells. (C–F) Localization of CPMV in splenocytes stained with: (C) PE
anti-CD8a (red), (D) PE anti-CD11c (red), (E) PE anti-B220 (red), and (F) PE anti NK 1.1 (red). The cell samples were visualized under a fluorescence
microscope using a 20X objective. The virus particles are in green and the nuclei are in blue.
doi:10.1371/journal.pone.0007981.g004
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PLoS ONE | www.plosone.org 7 November 2009 | Volume 4 | Issue 11 | e7981Figure 5. Quantitative analysis of CPMV uptake by different subpopulation of APCs in vivo. (A) Groups of three C57BL/6 mice were
inoculated: intraperitoneally (black columns) or intraveously (white columns) with 100 mg of CPMV-AF488. After 4 hours, spleens were removed and
the cells stained to analyze the internalization of the CPMV into CD11c
+/CD8a
+ cells (lymphoid DCs), CD11c
+/CD8a
2 cells (myeloid DCs), CD11c
+/
B220
+ cells (plasmocytoid DCs), CD11c
2/CD11b
+ cells (macrophages), B220
+/CD11c
2 cells (B-lymphocytes), and NK1.1
+ cells (natural killer cells). After
staining, the cells were fixed and analyzed by FACS. The columns represent the percentage of CPMV positive cells from each subpopulation of cells.
Mice inoculated with PBS were used to subtract the background. (B) Groups of three C57BL/6 mice were inoculated by oral gavage using 1000 mgo f
CPMV-AF488. After 20 hours, spleens were removed and treated the same way as described above. (C) Splenocytes were isolated from C57BL/6 mice
and red blood cells were removed. Dendritic cells remain in the connective tissue and do not flow through the cell strainer. Remaining cells were
blocked and stained (CD11b for macrophages, B220 for B cells, NK1.1 for natural killer cells, and v4630 anti-vimentin antibody for vimentin). Cells
were then fixed and analyzed by FACS.
doi:10.1371/journal.pone.0007981.g005
Figure 6. In vivo uptake of CPMV particles in intestinal PP. (A) Fluorescence microscopy image showing CPMV-AF488 particles (green)
penetrating the dome region of an intestinal PP. (B) Fluorescence microscopy image showing UEA Rhodamine M cell marker (red). (C) Merge A and B.
(D) FACS analysis of CD11c positive PP DCs. CPMV positive lymphoid, myeloid and double negative PP DCs expressed as a percent of each respective
PP DC subpopulation.
doi:10.1371/journal.pone.0007981.g006
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nanoparticles have been shown to interact with APCs [14,51].
Porcine parvovirus (PPV) VLPs are captured by lymphoid and
myeloid DCs after iv inoculation [51], papaya mosaic virus
(PapMV) VLPs are captured by CD11c
+ DC after iv inoculation
[14] and the polystyrene nanoparticles are taken up into
pulmonary DCs following intranasal administration. PPV, PapMV
VLPs and polystyrene nanoparticles can, much like CPMV, act as
potent vaccines able to generate humoral immune responses [52]
and can also induce cellular immunity [14,51,53]. Previous studies
have also shown the capacity of imDCs to internalize other types
of particulate antigens in vitro, including gelatin nanoparticles
(88%), polystyrene nanospheres and poly (D, L-lactic acid-co-
glycolic acid) (PLGA) nanoparticles (58–75%) [28,29,54].
We also compared the proportion of different APC populations
internalizing CPMV particles following oral, intravenous or
intraperitoneal administration. The percentage of APCs contain-
ing CPMV particles in the spleen following oral gavage was 10 to
100 fold lower in comparison with i.v. or i.p. routes of inoculation.
This phenomenon is likely due to a smaller percentage of the
particles transported across the intestinal epithelium. In addition,
the lower signal could partly be due to the 20–40% removal of the
particle-dye linkage we previously observed in the gastrointestinal
tract [26]. At the same time it is possible that APCs present in the
intestinal epithelium capture CPMV particles and remain in the
PP or migrate to the mesenteric lymph nodes (MLN), thus
decreasing the amount of free particles in circulation.
In this study, we showed that CPMV co-localized with M cells
and cells within the PP in intestinal epithelium. We had previously
demonstrated the ability of CPMV to access the mammalian
systemic circulation and enter into a variety of tissues following
oral administration, including the spleen [26]. However, the
mechanism of translocation across the intestinal epithelia was
unknown, and these studies suggest that such translocation occurs
via the PP. In general there are three major routes that viruses,
bacteria, parasites and macromolecules use to cross the epithelial
mucosa: the transcellular route, the paracellular route across cell-
to-cell junctions including tight junctions, and via M cells [55]. M
cells are specially differentiated epithelial cells in PP, which are
located along the antimesenteric side of the small intestine and are
most prominent in the terminal ileum. M cells are specialized in
capturing and delivering macromolecules, particles, and pathogens
into the subepithelial dome region of PP, an area rich in dendritic
cells. M cells efficiently transport latex particles, polystyrene
microparticles, and viruses including reovirus type 1, HIV type 1
and mouse mammary tumor virus, poliovirus type 1 [55].
Interestingly, both poliovirus and CPMV are structurally-related
members of the picornavirus superfamily, and their conserved
structural properties may facilitate M-cell interactions.
Once the antigens are transported by the M cells, the first cells
that the antigen encounters are most likely DCs present just
underneath or within the follicle-associated epithelium of the PP.
In the present study we showed that DCs present in the PP SED
captured CPMV particles in vivo. Oral administration of virus-sized
fluorescent polystyrene microparticles to mice results in detection
of fluorescent signal in double negative DCs in the SED, and none
in the lymphoid or myeloid populations [56]. When DCs are
activated after antigen ingestion they may migrate to other zones
in the PP or to the MLN. Polystyrene microparticles by themselves
do not induce migration, as they remain in the SED for up to 14
days [56]. However, DCs loaded with polystyrene microparticles
migrate into T-zones and to B-cell follicles in the PP upon cholera
toxin treatment. DCs migration from PP to MLN has also been
detected in mice after ingestion of bacteria along with fluorescent
particles [57]. We do not know if CPMV particles induce
migration of PP DC.
As we have shown in this study, DCs, macrophages and B cells
efficiently capture CPMV particles. CPMV chimeras displaying
foreign antigenic epitopes have been successfully used as vaccines
to prime B-cell responses, but it has not been possible to prime T-
cell responses using CPMV as had been reported for several other
virus-like particles (PPV [51] and papaya mosaic virus [14]). Thus,
in order to prime T-cell responses a more specific understanding of
the uptake mechanisms and processing of CPMV-displayed
epitopes in comparison to other VLPs is appropriate. Further
studies to characterize the CPMV-APC interaction will provide
the essential information required for design and development of
CPMV based vaccine systems.
Materials and Methods
Mice
Adult female C57 BL/6 (H-2b) mice were purchased from the
Scripps Research Institute breeding colony and housed in specific
pathogen-free conditions. All animal studies were approved by the
Scripps Institutional Animal Care and Use Committee (IACUC).
Cell Culture
MC57 fibroblast cells were grown in RPMI-1640 supplemented
with 7–10% heat-inactivated fetal bovine serum (FBS), 2 mM L-
glutamine, 100 U/ml penicillin G, and 100 mg/ml streptomycin
(all from Gibco-BRL, Rockville, Md.). BalbCl7 fibroblasts and
Caco-2 cells were grown in minimum essential media (MEM) with
the above supplements. Bone-marrow derived DCs were isolated
and cultured following the procedure of Lutz et al. [46].
Propagation and Purification of CPMV
CPMV resuspended at 25 ng/ml in 0.1 M K-phosphate buffer
was used as inoculum for passage to new cowpea plants to produce
virus-working stocks. CPMV was purified from the infected leaves
by standard methods described by Rae et al. [26]. The final virus
pellets were resuspended in PBS (Gibco-BRL) and filter-sterilized
through a 0.2 mm membrane (Costar). Virus concentration was
measured spectrophotometrically. The CPMV images from wild-
type virus particles and the CPMV-vEFa chimera were created
using the Visual Molecular Dynamics software [58].
Chemical Coupling of Fluorescein and AlexaFluor 488
Dyes to CPMV
Fluorescein-5-maleimide dye (Molecular Probes) was coupled to
cysteines on the coat protein of the CPMV-vEFa chimera (gift
from Dr. J. Johnson) as previously described by Wang et al. [20]
with the following modifications. The dye (2.28 mg) was
resupended in 1 ml of DMSO and mixed with 5 mg of CPMV
in 0.1 M K-phosphate buffer (molar ratio of 100 dyes per
asymmetric large-small coat protein unit) in 5 ml final volume and
incubated 72 hours at 4uC. To conjugate dyes to lysines on wild-
type CPMV, 1 mg Alexa fluor 488 carboxylic acid, succinimidyl
ester (Molecular Probes) was resuspended in 0.1 M K-phosphate
buffer and mixed with 5 mg of CPMV in a total volume of 1 ml of
the same buffer using a molar ratio of 30 dyes per asymmetric
large-small coat protein unit. The virus-dye suspension was
incubated at room temperature in a rolling shaker for 24–
72 hours. After incubation the samples were initially purified by
ultracentrifugation (Beckman Coulter, L-90K ultracentrifuge) in a
50.2 Ti rotor at 42,000 rpm (3 hours, 4uC) and resuspended in
1 ml of the same buffer. To eliminate free dye the sample was
further purified by a sucrose gradient (30%–10%) ultracentrifu-
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collecting the labeled CPMV fractions the virus was concentrated
by ultracentrifugation in a 50.2 Ti rotor at 42,000 rpm (3 hours,
4uC). The final pellet was resuspended in PBS (Gibco-BRL) and
filtered through a 0.2-mm membrane (Costar) to eliminate particle
aggregates. The dye concentration was obtained measuring the
absorbance of the sample at 495 nm and using the molar
extinction coefficient (M) of the dye; 86000 for fluorescein and
71000 for AF488 respectively. The number of dyes per virus
particle obtained was 71.33/virus for Alexa Fluor 488 and 23/
virus for fluorescein, where dyes/particle=Abs4956dilution6MW
of CPMV/M6g of CPMV, where CPMV MW=5.6610
6 g/mol.
CPMV-AF488 particles used for the combined vimentin and
CPMV uptake studies using BalbCl7 mice resulted in 150 dyes/
virus particle.
CPMV Binds to Cell Surface of APCs
The cell lines MC57 and BalbCl7, and primary DCs were
cultured in 6 well plates, fixed with paraformaldehyde and
incubated with CPMV-AF488 (6.8 mg/ml) overnight at 4uC. After
extensive washing with PBS, cells were stained with DAPI and
visualized with a Zeiss Axiovert S100 immunofluorescent
microscope (20X objective). For FACS analysis, 9 or 10 days
differentiated DCs were added to a V-bottom 96 well plate
(5610
5 cell/well) and incubated with 1 mg of CPMV-AF488
particles (1610
8 particles) for 3 hours on ice. Then cells were
stained with the antibodies allophycocyanin (APC) anti-CD11c
(clone N418) from eBioscience Inc., R-Phycoerythrin (R-PE) anti-
CD11b (Mac-1; clone M1/70), R-PE anti-CD86 (B7.2; clone
GL1) and R-PE anti-CD80 (B7.1; clone 16-10A1) from BD
PharMingen, fixed using formaldehyde 2% in PBS and acquired
by FACS. For the binding competition assay 1610
6 or 5610
5 DCs
were stained with the above anti-CD11b and anti-CD11c
antibodies and incubated overnight on ice with different amounts
of unlabeled CPMV (0 mg, 1 mg, 10 mg, 100 mg, and 1000 mg).
After washing and incubating with 1 mg of CPMV-AF488 for
3 hours on ice, the cells were washed, fixed using formaldehyde
2% in PBS, acquired on a FACSort flow cytometer (50,000 events)
and analyzed with FlowJo software (Treestar, San Carlos, CA).
Surface Vimentin Expression
For flow cytometry, the cell lines MC57, BalbCl7, Caco-2, and
RAW macrophages were cultured in flasks and collected into V-
bottom 96 well plates (125610
5 cells/well). Splenocytes and
Peyer’s patch cells were collected from mice as previously
described. Cells were stained with vimentin antibody V4630
followed by staining with Alexafluor 647 conjugated to donkey
anti-goat antibody. They were fixed with 2% EM grade
formaldehyde for 15 minutes and then acquired on a FACSort
flow cytometer (10,000 events) and analyzed with FlowJo software
(Treestar, San Carlos, CA).
For confocal microscopy, Caco-2 cells were seeded into glass-
bottom culture dishes (Mat-tek) at 50,000–100,000 cells in 3 ml
media per dish and grown overnight. The following day, cells were
fixed for 10 minutes at room temperature in 3% EM grade
formaldehyde and 0.3% gluteraldehyde in PBS. Cells were washed
and blocked for one hour in PBS with 5% normal goat serum
(NGS). Cells were then incubated with vimentin antibody V9
(1:100) for 1.5 hours in 1% NGS PBS. Cells were washed and
secondary antibody, chicken anti-mouse conjugated to Alexafluor-
647 (1:200) was added in 1% NGS PBS for one hour. Cells were
washed and incubated one hour with wheat germ agglutinin
conjugated to Alexafluor-555 (1:500) in 1% NGS PBS. During the
final 10 minutes, DAPI (1:9500) was added in PBS. Cells were
washed, and the cells were mounted in Immunofluore Mounting
Medium. Cells were visualized at 60x with a Bio-Rad Radiance
2100 Rainbow laser scanning confocal microscope. All incubations
take place at room temperature on a slow rock. Following each
incubation, cells were washed four times in PBS in order to
remove antibody that is bound nonspecifically.
Cellular Uptake of CPMV In Vitro
MC57 and BalbCl7 cells (200,000 and 80,000 cells/well
respectively) were cultured on Lab-Tek II chamber polylysine
slides (Nalge Nunc Naperville, IL) and CPMV-FITC was added to
the media. DCs were cultured in 24 well plates with CPMV-
AF488. Cultures were incubated overnight at 37uC and 5% CO2.
Cells were washed 3 times with PBS, fixed with 2% formaldehyde,
stained with DAPI and visualized with a Zeiss Axiovert S100
immunofluorescence microscope. DCs were stained with the
specific antibodies markers as indicated above. Cells were fixed
using 2% formaldehyde in PBS, acquired on a FACSort flow
cytometer (30,000 events per sample) and analyzed with FlowJo
software (Treestar, San Carlos, CA).
For correlation of CPMV uptake and presence of surface
vimentin, BalbCl7 cells were cultured and incubated with CPMV-
AF488 for 3 and 24 hours at 37uC and 5% CO2. Cells were
washed and fixed in 2% formaldehyde and incubated with
antibodies specific for vimentin. After washing, the cells were
stained with a secondary antibody, washed, and acquired on a BD
Digital LSR II and analyzed with FlowJo software.
Cellular Uptake of CPMV In Vivo
Groups of 3 mice each were inoculated i.v. or i.p. with 100 mg
or by oral gavage with 1 mg of CPMV-AF488. Negative control
mice were inoculated with PBS. Four hours after i.v. or i.p. and
20 hours after oral gavage mice were sacrificed and the spleens
harvested. The spleens were injected with 1 ml solution of 1 mg/
ml of Collagenase-D (ROCHEeim) in RPMI medium, then cut in
small pieces and incubated at 37uC for 15 min. To disrupt T-cell-
DC complexes 4 ml of 0.5 M EDTA were added to the cell
suspension and incubated at 37uC/5 min. After collagenase-D
treatment a single cell suspension of splenocytes were prepared
according to standard procedures. The cells (2610
6) were washed
once with FACS buffer (1% FBS and 0.1% Na-azide in PBS) and
nonspecific binding was blocked for 10 minutes on ice using rat
anti-mouse CD16/CD32 antibody in FACS buffer (clone 2.4 G2,
BD PharMingen). The cells were stained with the following rat
anti-mouse monoclonal antibodies: APC anti-CD11c (clone N418)
and PE anti-NK 1.1 (clone PK136) from eBioscience; R-R-PE
anti-CD8a (clone 53–6.7), R-PE anti-CD11b (clone M1/70), R-
PE anti-CD45R/B220 (clone RA3-6B2) from BD PharMingen
and fixed in 2% formaldehyde in PBS. Cells (100,000 events per
sample) were acquired on a FACSCalibur flow cytometer (Becton
Dickson, San Jose, CA) and analyzed with FlowJo software
(Treestar, San Carlos, CA). Spleen cells from i.p. inoculated mice
were also visualized by fluorescence microscopy as described
above.
Ileal Loop Inoculation with CPMV-AF488 and PP Analysis
C57 BL/6 mice were anesthetized with an i.p. injection of
500 ml Avertin (2,2,2 tribromoethanol) solution at 20 mg/ml.
Intestinal loops of approximately four cm containing a single PP
were constricted and inoculated with 200 mg CPMV-AF488 and
20 mg UEA Rhodamine (Vector Laboratories) M cell binding
lectin in a PBS solution of 450 ml total volume. Mice were
incubated under anesthesia and heat for one hour. Following
incubation, the loops were harvested and gently flushed with PBS.
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mounted in OCT medium for cryosectioning. For flow cytometry
analysis PP were inoculated only with CPMV-AF488 treated with
collagenase D to prepare a single cell suspension and stained the
same way as described for the spleens, but using the antibody
markers, APC-CD11c, PE-CD11b and Peridinin Chlorophyll-a
protein (PerCP)-CD8a (clone 53–6.7) (BD Pharmingen). Negative
controls were inoculated with PBS. For cryosectioning the loops
were inoculated with both CPMV and UEA and six micron
cryosections were made in a Leica cryomicrotome. The sections
were fixed in acetone, subjected to DAPI nuclear stain and
analyzed under a fluorescence microscope (Nikon Eclipse TS100)
using the 20X objective.
Supporting Information
Figure S1 Space-filling model of the CPMV structure. Created
using Visual Molecular Dynamics software (VMD) [57] showing
the S protein in green and the L protein in light grey. (A) Naturally
occurring exposed lysines are highlighted in red. (B) Cysteine
residues of a genetically modified CPMV (vEFa) particle are
highlighted in blue.
Found at: doi:10.1371/journal.pone.0007981.s001 (0.79 MB TIF)
Figure S2 Correlation of surface vimentin expression and ability
to take up CPMV. Flow cytometry profiles of BalbCl7 cells, both
unstained, non-incubated (A), and incubated with CPMV-AF488
(B–D). Cells in C and D were stained with primary vimentin
antibody and secondary, while B represents a secondary only
control. B and C were incubated with CPMV for 3 hrs, and D for
24 hrs.
Found at: doi:10.1371/journal.pone.0007981.s002 (1.44 MB TIF)
Figure S3 CPMV uptake by different subpopulation of APCs in
vivo. Flow cytometry profiles of splenocytes from noninoculated
mice and mice inoculated intraperitonealy with CPMV-AF488.
The figure shows the uptake profile of different subpopulations of
splenocytes.
Found at: doi:10.1371/journal.pone.0007981.s003 (2.86 MB TIF)
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